Global private-equity giant KKR has formally committed to investing up to US $200 million in its India-based medical-devices platform, Healthium Medtech, signalling another major bet on the country’s manufacturing resurgence.

According to industry reports, the funds roughly between US $150-200 million will be used as part of a bolt-on acquisition strategy, expanding Healthium’s portfolio beyond its current lines of business into new therapy areas such as cardiology, orthopaedics and diagnostics. The announcement follows KKR’s earlier acquisition of Healthium for approximately ₹7,000 crore.

India’s medical-devices sector is at a pivotal turning point: the domestic market is projected to surge towards US $50 billion over the next five years. This growth is being driven by rising healthcare demand, import substitution, policy incentives such as the PLI scheme and the push for “Make in India” manufacturing.

For KKR, the investment reflects a strategic focus on healthcare manufacturing building not just domestic scale but export capability. Healthium’s new capital will support setting up advanced manufacturing units, acquiring complementary manufacturing assets, and strengthening supply-chain infrastructure for high-growth device segments.

While large in size, the move also raises questions of execution: integrating acquired assets, maintaining compliance with global device-manufacturing standards, and managing cost pressures are all on the radar. For India, the investment underlines the growing confidence of global capital in the med-tech manufacturing story but whether scale-up is seamless remains to be seen.